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Demographic Characteristics, Survival and Prognostic Factors for
Mortality in Cats with Primary Immune-Mediated Hemolytic Anemia
J.W. Swann, B. Szladovits, and B. Glanemann
Background: Immune-mediated hemolytic anemia (IMHA) is uncommon in cats, but may result in severe disease. Demo-
graphic predispositions for development of the disease and prognostic factors for mortality have not been investigated previ-
ously.
Hypothesis/Objectives: To explore possible demographic predispositions for development of primary IMHA in cats and
to investigate possible prognostic factors for mortality.
Animals: 107 client-owned cats with IMHA, of which 72 had primary IMHA and 35 had secondary IMHA, and 9,194
control cats.
Methods: Data were collected retrospectively from records of cats with IMHA, defined by the presence of anemia and
concurrent autoagglutination, ghost cells without oxidative damage on fresh blood smear, positive titer in a direct antiglobu-
lin test, or evidence of phagocytosis of erythroid precursors in bone marrow. Odds ratios were calculated to assess the risk of
development of primary IMHA in different demographic groups and Cox proportional hazards analysis was conducted to
evaluate prognostic factors.
Results: No sex or breed predisposition was identified for the development of primary IMHA in comparison to the con-
trol cats, but cats in the age range 2.1–5.9 years were predisposed. Higher total bilirubin concentration and age were signifi-
cant negative prognostic factors and higher lymphocyte numbers and serum globulin concentration were positive prognostic
factors in a multivariable model.
Conclusions and Clinical Importance: Young adult cats were more likely to develop primary IMHA than other groups,
but no apparent male predisposition was identified in this study, contrary to previous reports. Several prognostic factors were
identified, which may be helpful in guiding clinical practice in the future.
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Immune-mediated hemolytic anemia (IMHA) occurswhen the body mounts an autoimmune response
against antigens expressed on the surface of erythro-
cytes.1 Autoreactive antibodies specific for cytoskeletal
components occur naturally in healthy dogs and people,
where they may play a role in removal of senescent ery-
throcytes from the circulation.2,3 In animals with
IMHA, production of antibodies results in destruction
of normal erythrocytes by inappropriate activation of
the complement cascade, antibody-dependent cytotoxic-
ity, or facilitated phagocytosis in the liver and spleen,
resulting in severe anemia.4
Early reports suggested that IMHA was more likely
to be secondary to an underlying infectious, inflamma-
tory, or neoplastic process in cats,5,6 and there appeared
to be a particular association between this disease and
concurrent feline leukemia virus (FeLV) infection. More
recent studies have suggested that the proportion of cats
with primary disease (83% of those with a positive
direct antiglobulin test) is higher, and similar to that
reported in dogs.7–9
Diagnosis of IMHA in cats traditionally has relied
on detection of antibodies bound to erythrocytes by
the direct antiglobulin test (DAT, direct Coombs’ test),
but the reported diagnostic accuracy of this test has
varied considerably among previous studies,10 with
positive results also observed in cats with other dis-
eases, including FeLV infection,6,11 hemotropic Myco-
plasma spp. infection,12 and inflammatory diseases
such as pancreatitis,8 cholangitis,8 and pyothorax.13
Persistent agglutination after dilution in saline has
been reported in a large proportion of cats with
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IMHA,5–7 but this finding also is considered to have
low specificity in cats because it also may occur in the
diseases listed above. Previous descriptions of IMHA
in cats have not discussed the presence of ghost cells,
which are partially lysed erythrocytes that retain their
shape and basic cytoskeletal structure. These cells indi-
cate intravascular hemolysis, which is most likely to be
associated with complement-mediated lysis,14 particu-
larly if signs of oxidative damage, such as Heinz bod-
ies, are absent. In contrast to dogs, detection of
spherocytes on a blood smear is not considered reli-
able for diagnosis of IMHA in cats because their nor-
mal erythrocytes are small and may lack central
pallor.1
Little information has been published on the natu-
ral history of primary idiopathic IMHA in cats. A
case series of 19 cats described several intriguing fea-
tures of the disease, including a high prevalence of
lymphocytosis and hyperglobulinemia, which are not
typical of IMHA in dogs and may suggest different
underlying immunologic changes in cats.7 A higher
proportion of cats with IMHA also had nonregenera-
tive anemia at diagnosis, but reticulocyte numbers
were reported to increase in the majority of these cats
after commencing treatment.7
More male than female cats were diagnosed with pri-
mary IMHA in 3 previous studies,6–8 but sex and breed
frequencies were not compared to control groups. Fol-
low-up of the cats also suggested that survival may be
more favorable in this species with a mortality rate of
23.5% overall, which is lower than the rate of 50–70%
that often is cited for IMHA in dogs.15 Prognostic fac-
tors for mortality have not been evaluated previously in
cats with IMHA.
The aims of this study were to evaluate possible age,
breed, and sex predispositions for development of pri-
mary idiopathic IMHA in cats, and to evaluate survival
times and possible prognostic factors for mortality in a
large cohort of cats with this disease.
Materials and Methods
Selection of Cases
The electronic medical record system of a tertiary referral hospi-
tal was searched between July 2005 and July 2014 for cats that
had a final diagnosis of IMHA, and the full records of selected
cases were obtained.
The following data were recorded for each case: signalment;
clinical examination findings; results of CBC, serum biochemical
profile, reticulocyte count, retroviral and hemotropic Mycoplasma
spp. testing, bone marrow, and any other cytologic or histologic
examinations; findings from thoracic and abdominal imaging;
blood type and records of blood product transfusion; and
immunosuppressive drugs administered. The reports of bone mar-
row analysis were reviewed by 2 of the authors, and, where data
were incomplete, the relevant samples were reviewed by a board-
certified clinical pathologist (BS).
Referring veterinarians were contacted by telephone to obtain
follow-up information. The study protocol was approved by an
institutional ethical review committee (reference number
2014_1303).
Case Definitions
Cats were considered to have IMHA if they fulfilled all 4 of the
following criteria:
1 Cat was anemic at presentation, with a hematocrit of <24%.
2 Cat showed signs suggestive of immune-mediated destruction
of erythrocytes by observation of ghost cells (without visible
Heinz bodies) on a fresh blood smear, or persistent micro-
scopic or macroscopic autoagglutination, or a titer of at least
1 : 16 in a DAT at 37C with polyvalent antisera, or evidence
of phagocytosis of erythroid precursors in bone marrow sam-
ples. Agglutination was assessed macroscopically on a glass
slide and microscopically after diluting 1 drop of whole blood
in a sufficient volume of 0.9% saline to eliminate rouleaux for-
mation. Fresh blood smears were evaluated after staining with
modified Wright’s stain; new methylene blue stains were
requested in cases with a hematocrit <20% or on the request
of the examining pathologist.
3 Cat did not have historical evidence or clinical signs of hemor-
rhage or exposure to oxidative toxins as the cause of anemia.
4 Cat was treated with immunosuppressive medications.
Cats were considered to have primary idiopathic IMHA if no
underlying cause of disease was detected. All cats underwent imag-
ing of the thorax and abdomen, CBC with examination of a fresh
blood smear, serum biochemical profile, and serologic tests for
FeLV and feline immunodeficiency virus (FIV). At the discretion
of the attending clinician, blood samples also were submitted from
some cats for polymerase chain reaction (PCR) for hemotropic
Mycoplasma spp. and bone marrow samples were collected for
cytologic examination, histologic examination, or both. Cats were
considered to have nonregenerative IMHA (a clinical descriptive
term) if the absolute reticulocyte count remained <50,000/lL for
at least 5 days after presentation.
Breed and sex were recorded for all other cats that were pre-
sented to the same institution during the same time period as the
cats with IMHA to act as a control population. For this group,
the age at presentation also was calculated for a random sample
of 504 cats. The results of all blood typing procedures in cats at
the same institution also were obtained over the same time period,
together with the breeds of the typed cats.
Statistical Analysis
All analyses were conducted using statistical software pack-
ages.a,b Variables were assessed for normality by visual assessment
of histograms and use of the Shapiro–Wilks test. Continuous vari-
ables were compared using Student’s t-test if normally distributed
or the Mann–Whitney U-test if not normally distributed. Categori-
cal variables were compared using Chi-squared test or Fisher’s
exact test, depending on the number of cases per cell.
Breed, sex, or age predispositions for the development of pri-
mary IMHA were assessed by the calculation of odds ratios, com-
paring the proportion of cats with primary IMHA with any
particular signalment feature to the proportion of control cats with
the same feature. Only breeds represented by at least 3 cats with
primary IMHA were considered. Cases and controls were stratified
into 4 balanced age groups based on calculation of the quartiles
for age distribution from the entire sample. Bonferroni corrections
were applied to P values to account for the effect of multiple com-
parisons.
Survival was assessed by Kaplan–Meier product limit esti-
mates, and differences between groups were assessed using the
log rank test. Cox proportional hazards analysis was used to
assess possible prognostic factors for mortality. Fifteen variables
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were selected based on their a priori importance and to decrease
redundancy and correlation between variables. Individual vari-
ables were first visualized as 3 groups using Kaplan–Meier pro-
duct limit estimates. Where there was an evident difference
between 1 group and the others, these variables were entered as
categorical variables. Where there was an ordinal change in sur-
vival, these variables were entered as continuous variables. Vari-
ables first were entered individually for univariable analysis and
all those with a P < .1 were entered into the multivariable model.
The model was constructed using manual backward selection
based on calculation of likelihood ratios, and the validity of the
proportional hazards assumption was determined by visual assess-
ment of the Schoenfeld residuals for each variable in the final
model.
Results
Diagnosis of IMHA
One hundred and seven cats were included in this
study, and the results of tests used to make the diag-
nosis of IMHA are shown in Table 1. A DAT was
performed in 11 cases: in 3 cats DAT produced a
titer ≥1 : 16, which was supportive of a diagnosis of
IMHA. Of the 8 cats with a titer of <1 : 16, ghost
cells were observed on a fresh blood smear in 5, per-
sistent agglutination after saline dilution was detected
in 7 and findings supportive of IMHA were observed
on examination of bone marrow samples in 1 cat.
Of the cats diagnosed with IMHA, 35 (32.7%) were
found to have an underlying disease that could have
caused secondary immune-mediated disease. These dis-
eases included neoplasia (n = 16), including lymphoma
(5), erythroleukemia (2), histiocytic sarcoma (1), multi-
ple myeloma (1), anaplastic sarcoma with giant cells
(1), and uncharacterized masses (6); infection with
FeLV (n = 1), Mycoplasma hemofelis (1), Mycoplasma
hemominutum (1), concurrent M. hemofelis and M.
hemominutum (1), or feline infectious peritonitis
(n = 3); cholangitis, pancreatitis or both (n = 6), uri-
nary tract infection and suspected pyelonephritis
(n = 1), and other inflammatory or infectious diseases
(n = 7).
Of the cats considered to have primary IMHA
(n = 72), immunochromatographic point-of-care tests
yielded a positive result for FeLV p27 antigen in 2
cases, but PCR for proviral DNA on EDTA-anticoa-
gulated blood subsequently were negative in both
cats. Point-of-care tests for antibodies to FIV were
negative in all cases. Quantitative polymerase chain
reactions for hemotropic Mycoplasma spp. were sub-
mitted in 62 cats and negative results were obtained
in all cases.
Demographic Data
Data describing age, breed, and sex in cats with pri-
mary IMHA (n = 72), cats with secondary IMHA
(n = 35) and all other cats presented to the institution
(n = 9,194) are shown in Table 2.
Cats with primary IMHA were significantly younger
than those with secondary IMHA (P = .031), but there
was no difference in the proportion of cats in these
groups that were male and female (P = .074).
Cats in the age range 2.1 to 5.9 years were 2.0 times
(95% confidence interval [CI], 1.19–3.41) more likely
to develop primary IMHA than all other age groups
combined (Table 3). Siamese cats also appeared to be
predisposed to development of primary IMHA com-
pared to all other breeds, but this association did not
reach significance after Bonferroni correction. No sex
group was predisposed to development of primary
IMHA.
Table 1. Criteria used to make the diagnosis of
IMHA. Percentages add up to more than 100% because
some cats were included in >1 group.
Diagnostic Criterion
Number
of Cats %
Number of Cats
in which this
was the only
Diagnostic Criterion
Fulfilled
Significant titer in
direct antiglobulin test
3 2.8 1
Persistent agglutination
(confirmed by saline
dilution)
70 65.4 10
Ghost cells observed on
fresh blood smear
62 57.9 5
Phagocytosis of erythroid
precursors observed on
bone marrow sample
23 21.5 7
Table 2. Demographic data from cats with primary
and secondary IMHA and control cats.
Variable
Cats with IMHA
Primary
Disease
Secondary
Disease Control Cats
Age (years)
Median 4.2 6.8 6.1
Interquartile
range
1.9–8.8 4.1–10.0 2.0–11.6
Range 0.2–17.9 0.5–18.0 0.1–23.0
N 72 35 504
Sex (N, %)
Intact male 2 (2.8) 0 525 (5.7)
Neutered male 30 (41.7) 22 (62.9) 4,744 (51.8)
Intact female 4 (5.6) 0 532 (5.8)
Neutered
female
36 (50.0) 13 (37.1) 3,351 (36.6)
N 72 35 9,152
Breed (N, %)
DSH 48 (66.7) 23 (65.7) 6,147 (66.9)
DLH 8 (11.1) 4 (11.4) 849 (9.2)
Siamese 4 (5.6) 3 (8.6) 204 (2.2)
Other 12 (16.7) 5 (14.3) 1,994 (21.7)
N 72 35 9,194
DSH, domestic short hair; DLH, domestic long hair.
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Clinical Data
Results of CBC and serum biochemical profiles for
cats with primary or secondary IMHA are shown in
Table 4. The lymphocyte count was significantly
higher in cats with primary IMHA (median: 2,400/lL;
interquartile range [IQR], 1,300–4,300; range:
420–20,280) compared to those with secondary IMHA
(1,000/lL; IQR: 600–2,200; range: 90–17,440;
P < .001; Fig 1), whereas the serum albumin concen-
tration was significantly lower in cats with secondary
IMHA (mean: 2.65  1.05 g/dL) compared to those
with primary IMHA (3.18  0.66 g/dL; P < .001).
Fifty-seven cats with primary IMHA were blood
typed, and the majority were type A (n = 45, 78.9%)
and a smaller number were type B (n = 9, 15.8%) or
AB (n = 3, 5.3%). Three hundred and sixty-nine cats
without IMHA were typed over the same time period
as this study, of which 277 (75.1%) were type A, 70
(19.0%) were type B, and 22 (6.0%) were type AB. Cats
of 1 particular blood type were not at increased risk of
development of primary IMHA (Table 3), and there
was no difference in the proportion of cats belonging to
each blood type among groups.
The median absolute reticulocyte concentration
(ARC) for all cats with IMHA on presentation was
32,850/lL (IQR: 9,160–106,640; range: 0–795,400), and
did not differ between cats with primary or secondary
IMHA (Table 4, P = .861). Forty (55.6%) cats with
primary IMHA had an ARC < 50,000/lL on presenta-
tion, and, of these, 16 failed to show evidence of
appropriate regeneration within the next 5 days after
starting to receive immunosuppressive treatment, 18
did become regenerative, 3 died within the first 5 days,
and 3 did not have a repeat blood sample at an
appropriate time to determine whether the reticulocyte
count had changed. The proportion of cats with non-
regenerative anemia 5 days after presentation did not
differ between those with primary IMHA (16/63,
25.4%) and those with secondary disease (8/27, 29.6%,
P = .677).
Comparisons of age, hematologic and serum bio-
chemical variables between cats with primary IMHA
with either regenerative anemia or persistently nonre-
generative anemia did not identify any significant dif-
ferences between groups after Bonferroni correction
(Table S1) aside from the expected difference in ARC.
Cats with nonregenerative IMHA had lower serum
bilirubin concentrations, higher hematocrits and lower
mean corpuscular volume, and red cell distribution
width, but these differences were not significant.
Of the cats with primary IMHA, 55 had concurrent
deficiency of ≥1 other blood cell types, including 44
with thrombocytopenia (platelet concentration
<200,000/lL), 12 with neutropenia (<2,500/lL), and 24
with lymphopenia (<1,500/lL).
Bone Marrow Findings
Bone marrow aspirates were obtained from 60 cats
with IMHA, of which 13 (21.7%) samples were consid-
ered to be poorly diagnostic. Core biopsies were
obtained from 46 cats, with 16 (34.8%) of samples
Table 3. Age, sex, and breed predispositions for cats with primary IMHA compared to control cats.
Variable
Number of Cats with
Primary IMHA (%)
Number of Control
Cats (%) Odds Ratio
95% Confidence
Interval P Value
Agea
0–2.05 20 (27.8) 127 (25.2) 1.14 0.65–1.98 .652
2.06–5.90 26 (36.1) 110 (21.8) 2.01 1.19–3.41 .008
5.91–11.01 14 (19.4) 135 (26.8) 0.66 0.35–1.22 .178
11.02–23.50 12 (16.7) 130 (25.8) 0.57 0.29–1.10 .090
N 72 504
Sexa
Intact male 2 (2.8) 525 (5.7) 0.47 0.12–1.93 .440
Neutered male 30 (41.7) 4,744 (51.8) 0.67 0.42–1.07 .093
Intact female 4 (5.6) 532 (5.8) 0.96 0.35–2.64 1.000
Neutered female 36 (50.0) 3,351 (37.1) 1.74 1.10–2.77 .017
N 72 9,192
Breedb
DSH 48 (80.0) 6,147 (85.4) 0.99 0.61–1.62 .972
DLH 8 (13.3) 849 (11.8) 1.23 0.59–2.57 .584
Siamese 4 (6.7) 204 (2.8) 2.59 0.94–7.17 .078
N 60 7,200
Blood typeb
A 43 (75.4) 277 (75.1) 0.98 0.51–1.87 .952
B 9 (15.8) 70 (19.0) 1.25 0.59–2.67 .565
AB 5 (8.8) 22 (6.0) 0.66 0.24–1.82 .418
N 57 369
DSH, domestic short hair; DLH, domestic long hair.
aP value ≤.0125 indicates significance at .05 level after Bonferroni correction.
bP value ≤.0167 indicates significance at .05 level after Bonferroni correction.
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being poorly diagnostic. Major findings from bone mar-
row examination are shown in Table 5. In cases where
a bone marrow aspirate provided little information, a
diagnostic core biopsy was obtained in 7 (53.8%) cases.
Stainable iron and phagocytosis of erythroid precursors
were noted in samples from cats with primary and sec-
ondary IMHA (Fig 2A,B).
Further Characterization of Cats with Lymphocytosis
Eleven (15.3%) of the 72 cats with primary IMHA
had a lymphocyte count higher than the upper reference
limit (7,000/lL), and the distribution of lymphocyte
counts is shown in Figure 1. The median age of these
cats was 2.6 years (IQR: 1.8–4.8; range: 1.6–6.4). Bone
marrow samples were obtained in 7 cats, and lymphoid
cells constituted a median of 20% of the bone marrow
cells counted (IQR: 6–30) in these cases. The appear-
ance and organization of these lymphocytes varied, with
some arranged in distinct follicles or aggregates
(Fig 2C) and some spread diffusely throughout the bone
marrow cells.
Treatment of Cats with Primary IMHA
Sixty cats were discharged with PO medications, of
which 29 received only a glucocorticoid (either pred-
nisolone, n = 28 or dexamethasone, n = 1),c,d,e 22
received prednisolone and chlorambucil,f 6 received
prednisolone and cyclosporine,g 1 received only cyclos-
porine, and 2 received prednisolone, chlorambucil, and
cyclosporine. The average starting dosages of each drug
are shown in Table S2. Twenty-five cats received
courses of doxycyclineh after samples were submitted
for PCR for hemotropic Mycoplasma spp.
Fig 1. Lymphocyte concentrations in cats with primary or sec-
ondary IMHA. Lines represent median and interquartile range.
*p < 0.001.
Table 4. Hematologic and serum biochemical data from cats with primary and secondary IMHA.
Parameter Cats with Primary IMHA Cats with Secondary IMHA P Value
Red blood cell concentration (9106/lL) 2.07 (1.63–2.42) 2.41 (1.96–3.38) .016
Hematocrit (%, mean and standard error) 11.5 (0.45) 13.0 (0.70) .057a
Hemoglobin concentration (g/dL, mean
and standard error)
4.0 (0.14) 4.5 (0.23) .063a
Mean cell volume (fL) 54.0 (46.4–65.9) 48.8 (45.2–56.1) .086
Mean cell hemoglobin concentration 34.3 (32.1–37.0) 34.5 (31.9–36.6) .722
Red cell distribution width (%) 21.3 (18.6–24.8) 19.9 (17.7–23.6) .205
Nucleated red blood cells (per 100 leukocytes) 3.0 (0–11.0) 2.0 (0–6.0) .412
Absolute reticulocyte count (/lL) 32,480 (12,320–101,200) 38,600 (7,340–106,640) .861
Blood type
A 45 18 .336
B 9 7
AB 3 3
Total white blood cell count (9103/lL) 9.0 (6.1–14.2) 9.6 (5.6–19.1) .705
Neutrophil concentration 4.5 (3.2–8.0) 7.8 (3.8–15.3) .031
Band neutrophil concentration 0 (0–0.1) 0 (0–0.1) .595
Lymphocyte concentration 2.4 (1.3–4.3) 1.0 (0.6–2.2) <.001
Monocyte concentration 0.5 (0.2–0.9) 0.6 (0.2–1.0) .698
Eosinophil concentration 0 (0–0.2) 0 (0–0.09) 0.089
Platelet count (9103/lL) 150 (100–250) 150 (91–252) .832
Serum total protein concentration (g/dL) 7.0 (6.1–8.0) 6.4 (5.6–7.3) 0.049
Serum albumin concentration (g/dL) 3.2 (0.66) 2.7 (1.05) <.001a
Serum globulin concentration (g/dL) 3.8 (2.8–4.8) 3.5 (2.8–4.9) .844
Serum total bilirubin concentration (mg/dL) 0.4 (0.1–1.0) 0.5 (0.2–1.5) .327
Serum urea nitrogen concentration (mg/dL) 26 (19–34) 26 (20–36) .945
Serum creatinine concentration (mg/dL) 1.2 (1.1–1.4) 1.4 (1.0–1.7) .429
Serum ALT activity (U/L) 78 (44–158) 68 (37–127) .533
Serum ALP activity (U/L) 14 (6–28) 16 (10–32) .167
ALT, alanine aminotransferase; ALP, alkaline phosphatase.
Values are median and IQR and comparisons are by Mann–Whitney U-test unless otherwise stated. P values ≤.002 denote significance at
the .05 level following Bonferroni correction.
aStudent’s t-test.
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Temporal Changes in Hematocrit
Of the 65 cats with primary IMHA that survived for
>5 days after presentation, 25 (38.5%) recovered a nor-
mal hematocrit or packed cell volume of at least 25%
within 1 month of discharge from the hospital, of which
3 died before the month had elapsed. The normal
hematocrit or packed cell volume was not achieved
within 1 month in 23 cats (35.4%), of which 11 died or
were euthanized before the month had elapsed. Results
of follow-up blood samples were unavailable in 17 cats
(26.2%) during this period.
Survival Data
Not including those cats that died or were euthanized
while hospitalized, the median follow-up time for all
cats with IMHA was 239 days (IQR: 41–781), with 3
cats lost to follow-up after discharge. The median sur-
vival time for cats with primary IMHA (n = 71) was
516 days (first quartile 22 days, third quartile not
reached) and 14 days (IQR: 4–504) for cats with sec-
ondary IMHA (n = 33). Of the cats with complete fol-
low-up for at least 6 months after diagnosis, 35 of 59
(59.3%) with primary IMHA were still alive at
6 months, compared to 8 of 31 (25.8%) cats with sec-
ondary IMHA. Survival curves for both groups are
shown in Figure 3, and there was a significant difference
in survival time between the 2 groups (P < .001) and in
the proportion of cats alive at 6 months (P = .002).
Prognostic Factors
Fifteen variables were evaluated as possible prognos-
tic factors for mortality in cats with primary IMHA,
and results of univariable Cox proportional hazards
analysis are shown in Table 6. Seven variables (lympho-
cyte count, serum globulin concentration, serum total
bilirubin concentration, age, heart rate on presentation,
neutrophil count and serum alanine aminotransferase
[ALT] activity) were taken forward to multivariable
analysis, of which the first 4 were retained in the final
model, which is shown in Figure 4. There were no sig-
nificant interactions among variables included in the
final model, and violations of the proportional hazards
assumption were not detected on assessment of the
Schoenfeld residuals.
Discussion
This study describes the largest reported cohort of
cats with primary idiopathic IMHA and shows that cats
in the age group from 2 to 6 years were more likely to
develop the disease than other age groups, but that nei-
ther sex and no individual breed was predisposed. The
majority of cats with IMHA did not have any underly-
ing cause for the disease and therefore were considered
to have idiopathic IMHA. Survival time was signifi-
cantly longer in cats with primary IMHA compared to
those with secondary IMHA, and Cox proportional
hazards analysis identified higher serum bilirubin con-
centration and older age as significant negative prognos-
tic factors for mortality and higher lymphocyte
concentration and higher serum globulin concentration
as positive prognostic factors.
In this study, IMHA was most commonly diagnosed
in cats with persistent agglutination and in cases where
ghost cells were observed on fresh blood smears. These
findings have been reported in cats with other dis-
eases,4,16 but we believe that these abnormalities are
suggestive of primary immune-mediated hemolysis in
anemic cats with no other detectable diseases or signs
of oxidative hemolysis.
Direct antiglobulin tests were requested in a minority
of cases that were ultimately diagnosed with primary
IMHA because the test was considered unnecessary
when autoagglutination or ghost cells were detected in
the absence of any other cause of moderate or severe
anemia. Traditionally, there also were concerns that the
DAT had an unacceptably low specificity for diagnosis
Table 5. Results of cytologic and histopathologic examination of samples of bone marrow from cats with primary
or secondary IMHA.
Parameter
Cat with primary
IMHA (n = 47)
Cats with secondary
IMHA (n = 18) P value
Myeloid: erythroid ratio (IQR) 0.30 (0.20–0.70) 0.55 (0.37–1.35) .130a
Proportion of lymphocytes observed (IQR) 8 (2–25) 6 (3.5–12.5) .429a
Stainable iron deposits observed (n, %) 5 (11.4%) 8 (44.4%) .004b
Erythrophagocytosis observed (n, %) 16 (34.0%) 10 (55.6%) .128b
Major features observed (n)
Erythroid hyperplasia 36 15
Erythroid hypoplasia or aplasia 6 2
Myeloid hyperplasia 7 9
Megakaryocytic hyperplasia 9 5
Lymphoid hyperplasia 14 1
Dyserythropoiesis, including maturation arrest 6 0
Neoplastic infiltration, including erythroleukemia 0 3
Values are presented as median and IQR, unless stated otherwise.
aMann–Whitney U-test.
bChi-squared test.
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of IMHA because clinically relevant titers were
obtained from nonanemic cats in a previous study.11
A more recent study using a more complete panel of
monovalent antisera directed against IgM and IgG iso-
types indicated that a clinically relevant positive titer
with either monovalent or polyvalent antisera at 37C
had a sensitivity of 81% and specificity of 92% for
diagnosis of IMHA,8 suggesting that this DAT should
A
B
C
Fig 2. (A) Bone marrow core biopsy section of a cat with numer-
ous foci of iron (H&E stain, 400x). Inset: stainable iron in the
same sample (Perl’s Prussian Blue stain, 1000x). (B) Bone marrow
aspirate from a cat. Macrophage on the right with four intact ery-
throid precursors phagocytosed, including a basophilic rubricyte, a
polychromatophilic rubricyte, and two metarubricytes (Modified
Wright’s stain, 1000x). (C) Prominent lymphoid follicle in a core
biopsy section of feline bone marrow (H&E stain, 200x).
Fig 3. Kaplan–Meier survival curve to compare survival times in
cats with primary IMHA (solid line) and those with secondary
IMHA (dashed line). Tick marks indicate censored cases.
Table 6. Results of univariable Cox proportional
hazards analysis for assessment of potential prognostic
factors for mortality in feline primary IMHA.
Variable
Univariable Analysis
Hazard
Ratio
95% Confidence
Interval P Value
Age* 1.159 1.074–1.251 <.001
Rectal temperature 0.800 0.535–1.196 .277
Heart rate 0.990 0.975–1.005 .179
Respiratory rate 1.003 0.985–1.022 .742
Neutrophil count 1.033 0.987–1.080 .163
Lymphocyte count*
(>2,500/lL)
0.436 0.211–0.902 .025
Hematocrit 0.999 0.918–1.088 .990
Type of anemia
(nonregenerative)
0.765 0.311–1.882 .560
Platelet count 1.000 0.998–1.002 .664
Serum albumin
concentration
0.734 0.375–1.435 .365
Serum globulin
concentration*
0.642 0.452–0.912 .013
Serum creatinine
concentration
1.010 0.523–1.952 .976
Serum ALT activity*
(≥85 U/L)
0.517 0.239–1.116 .093
Serum total bilirubin
concentration*
1.255 1.005–1.567 .046
Autoagglutination
(confirmed by
saline dilution)
1.050 0.505–2.181 .897
ALT, alanine aminotransferase.
*Variables considered in multivariable regression.
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be considered as a diagnostic test more frequently, par-
ticularly in those cases without convincing autoaggluti-
nation or ghost cells. The relatively low sensitivity of
the DAT may create difficulties if used as a sole diag-
nostic test because cases of presumed primary IMHA
have been reported in the absence of a clinically rele-
vant titer, both in a previous study6 and in the current
investigation.
This study has a number of limitations, chiefly related
to its retrospective design. There was some variation in
the diagnostic imaging modalities and types of infec-
tious disease testing among different cats. It is therefore
difficult to be sure that all cases were equivalent or clas-
sified into the correct groups. Some cats were still alive
or were lost to follow-up at the time that survival times
were calculated, which means that the Cox proportional
hazards model was based partly on censored data, as
indicated in Figure 3. Although it was possible to
describe dosages and types of medications used at com-
mencement of treatment in this study, it was difficult to
obtain complete treatment records for all cats after dis-
charge. We were therefore unable to consider the effect
of different treatment or tapering regimens as prognos-
tic factors in this analysis.
In this study, no underlying causes were detected in
the majority of cats diagnosed with IMHA, which is in
agreement with a recent study of the disease in Ger-
many.7 In previous studies in the 1970s and 1980s, a
substantial proportion of cases were found to be associ-
ated with FeLV infection, and we suggest that the dif-
ference could be related to the decreasing incidence of
FeLV infection in the face of widespread testing and
vaccination.17,18 The proportion of cats in this study
with IMHA and no underlying cause is similar to that
reported in dogs with IMHA,9,19,20 but the relative inci-
dences of the disease in the 2 species have not been
reported or compared to date.
In the majority of small descriptive case series, male
cats were diagnosed with IMHA more frequently than
females,5,7,8 but this association was not detected in our
study when sex distribution was compared to a large
group of cats presented to the same institution over the
same period of time. These findings are likely to be
related to the relative numbers of male and female cats
that were examined at our institution during the period of
the study, which was not taken into account in previous
studies of IMHA in cats. The predominance of male
cats presented for veterinary care has been reported pre-
viously in the emergency referral setting,21 but not in
first opinion practices in the United Kingdom,22 sug-
gesting that the caseload of individual institutions
should be assessed when investigating possible demo-
graphic associations for particular diseases.
Most reported cases of primary IMHA have been
diagnosed in young adult cats, with medians of
2 years,7 2.5 years,8 and 3.5 years5 stated in 3 previous
studies. We report a similar median age for cats with
primary IMHA in this study (4.2 years), and also show
that cats within the age range from 2.1 to 5.9 years
were significantly more likely to develop primary IMHA
than any other age group. This age of onset differs from
those reported in dogs and people, in whom the diagno-
sis is made more frequently in middle or older age
groups.23–25
Siamese cats appeared to be overrepresented among
the cases with primary IMHA, but this association did
not reach significance and the odds ratio had a large CI
because of the small number of Siamese cats with
IMHA. We cannot therefore conclude that any particu-
lar breed is predisposed to development of primary
IMHA, but the results of our investigation are in agree-
ment with previous studies that showed that the major-
ity of cases were diagnosed in genetically outbred
(domestic short-haired) cats.5,7,8
Clinical, hematologic, and biochemical data obtained
from cats with IMHA showed several similarities when
compared to previous studies. Severe anemia has been
reported in the majority of cats diagnosed with primary
IMHA, and the mean hematocrit of 11.5% in this study
is similar to results of recent investigations.7 Cats with
primary IMHA had a significantly higher lymphocyte
count than those with secondary IMHA, and lymphocy-
tosis was observed in 32% of cats with primary IMHA
in a previous case series.7 Lymphoid hyperplasia also
was observed on bone marrow samples in a large pro-
portion of cats in our study, and this feature has been
described previously in cats with IMHA.26
Immune-mediated hemolytic anemia commonly is
associated with chronic lymphocytic leukemia (CLL) in
people,27 and this possibility could not be excluded
completely in the cats with lymphocytosis and increased
numbers of bone marrow lymphocytes in this study.
Fig 4. Forest plot to show the variables included in the final multivariable model constructed using Cox proportional hazards analysis.
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There is no single reliable test to differentiate between
the 2 diseases in cats, and a final diagnosis usually is
based on consideration of the signalment, magnitude,
and chronicity of the lymphocytosis and phenotypic
and genotypic characteristics of the lymphocyte popula-
tion.26,28 According to these criteria, we consider it unli-
kely that the cats with peripheral lymphocytosis in this
study had CLL because all were younger than 7 years
at presentation and because the lymphocytosis resolved
rapidly with treatment in all cases. Severe anemia is not
reported to be a common feature of cats with CLL,
whereas lymphocytosis and increased numbers of bone
marrow lymphocytes have been reported consistently in
cats with IMHA and pure red cell aplasia.7,26,29
Immunophenotyping of peripheral lymphocytes was
requested in 1 cat in this study, and indicated a pre-
dominance of B cells, which also was more suggestive
of reactive proliferation28,i Although the phenotype and
functional characteristics of lymphocytes in cats with
IMHA have yet to be investigated, we hypothesize that
these may represent B cells specific for autoantigens,
and some of these B cells ultimately may differentiate
into plasma cells and produce autoantibodies.
Using Cox proportional hazards analysis, several
prognostic factors were identified for mortality in cats
with primary IMHA. Age of the patient often is consid-
ered to have an impact on survival, but this variable
was retained when the majority of cases were diagnosed
in cats <9 years of age. Serum bilirubin concentration
and clinically detectable icterus have been identified as
negative prognostic factors for mortality in several stud-
ies of IMHA in dogs,9,30–32 and this result probably is
related to the severity of hemolysis. Increased serum
bilirubin concentration also could be associated with
hepatic dysfunction caused by hypoxia and to forma-
tion of hepatic or portal thomboemboli, although the
latter complication was only detected in 1 cat in this
study by ultrasonography. Higher serum globulin con-
centration and lymphocyte count were associated with
improved survival times, but the cause of this relation-
ship was not apparent. As discussed above, increased
serum globulin concentration and lymphocyte count
traditionally have raised concerns that hemolysis could
be related to underlying disease, but they also could be
features of a form of IMHA that results in more
marked lymphocyte (possibly B cell) proliferation, but
that is more responsive to treatment.
As reported previously,6,7 a large proportion of cats
with primary IMHA had an ARC of <50,000/lL at
diagnosis, but many then developed a robust regenera-
tive response within the next 5 days. Lack of regenera-
tion by 5 days after diagnosis did not have an
independent effect on survival time, which suggests that
this group of cats may still respond to immunosuppres-
sive treatment and may have a similar long-term prog-
nosis compared to cats that have a regenerative
response at diagnosis.
Approximately 35% of cats with primary IMHA that
survived the first 5 days after presentation to the hospi-
tal went on to recover a normal packed cell volume or
hematocrit within 1 month, and the mortality rate in
this group was lower than among those cats that did
not attain a normal value within this time period. These
results should be interpreted with caution because data
were unavailable for a large proportion of cats and
because there was no systematic program of follow-up
testing after discharge, so that recovery of a normal
value may have been detected sooner in cats that were
being tested more frequently. Similarly, although the
speed of recovery of normal erythroid parameters is
likely to be an important prognostic factor, we chose
not to include this variable in our prognostic model
because we considered that the data were of insufficient
quality to draw conclusions.
In summary, we showed that primary IMHA occurred
more commonly than secondary IMHA, that male cats
were not predisposed to the disease, and that several
prognostic factors had a significant association with
mortality. The findings of this study ideally would be
confirmed by prospective investigations, which also
would permit assessment of the efficacy of different ther-
apeutic protocols and tapering regimens. Because the
disease is not diagnosed commonly, representing just
1.2% of cats presented to our specialist veterinary hospi-
tal, the feasibility of such studies remains questionable.
Footnotes
a IBM SPSS Statistics for Windows, Version 20.0, IBM Corp,
Armonk, New York
b GraphPad Prism version 6.00 for Windows, GraphPad Software,
La Jolla, California
c Prednicare (5 mg prednisolone tablets), Animalcare Ltd, York,
UK
d Prednidale (25 mg prednisolone tablets), Dechra Ltd, Stoke-on-
Trent, Staffordshire, UK
e Dexamethasone (2 mg tablets), Auden Mckenzie (Pharma Divi-
sion) Ltd, Ruislip, Middlesex, UK
f Chlorambucil (2 mg tablets), Aspen Pharma Trading Ltd,
Dublin, Ireland
g Atopica (cyclosporine, 100 mg/mL oral solution), Novartis Ani-
mal Health UK Ltd, Camberley, Surrey, UK
h Ronaxan (20 mg doxycycline tablets), Merial Animal Health
Ltd, Harlow, Essex, UK
i Workman HC, Vernau W, Schmidt PS et al. Chronic lympho-
cytic leukemia in cats is primarily a T helper cell disease. Pre-
sented at the 55th Annual Meeting of the American College of
Veterinary Pathologists, Orlando, November 13–17, 2004
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Supporting Information
Additional Supporting Information may be found
online in Supporting Information:
Table S1. Comparisons of hematologic and serum
biochemical data from cats with primary IMHA with
either regenerative anemia or persistently nonregenera-
tive anemia. Values are median and interquartile range
and comparisons are by Mann–Whitney U-test unless
otherwise stated. P < .0025 denote significance at the
.05 level after Bonferroni correction.
Table S2. Starting doses of drugs used in the treat-
ment of primary IMHA in cats. Numbers of cats differ
from those stated in text as bodyweight was not
recorded for all cases to enable calculation of dose
rates.
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